Researchers find corticosteroids combo is most effective for COVID-19 cytokine storm treatment

Some immune systems have responded to coronavirus disease 2019 (COVID-19) infections by going into overdrive, resulting in an overzealous inflammatory response referred to as a cytokine storm. In a retrospective study of nearly 6,000 patients, researchers from The Feinstein Institutes for Medical Research and Northwell COVID-19 Research Consortium have identified the most effective immunomodulatory therapies to treat patients with evidence of this cytokine storm and improve patient survival.

A multidisciplinary team of investigators, led by Negin Hajizadeh, a pulmonary and critical care physician, and associate professor at the Feinstein Institutes, analysed the electronic health records of hospitalised COVID-19 patients across 12 of Northwell Health hospitals between March 1 and April 24, 2020. The results were published in CHEST, by Sonali Narain, assistant professor at the Feinstein Institutes, corresponding author, and team.

Patients were divided into one of six groups; no immunomodulatory treatment (standard of care), patients who received intravenous corticosteroids, anti-interleukin 6 antibody therapy (tocilizumab) or anti-interleukin-1 therapy (anakinra) alone or in combination with corticosteroids.

The results show that the most effective treatment was the combination of corticosteroids – such as dexamethasone – with tocilizumab when compared to standard of care. Additionally, there was an improvement if corticosteroids were used alone, or in combination with tocilizumab or anakinra when compared with standard of care.

“Cytokine storms are a hallmark for many COVID-19 patients and are associated with the most severe form of this illness,” said Dr Hajizadeh, associate professor at the Zucker School of Medicine at Hofstra/Northwell and co-senior author on the paper. Our findings suggest that with the intervention of certain drugs like corticosteroids, we can battle the cytokine storm and improve outcomes to the point that we believe we have found a new standard of care for seriously ill patients.”

Overall, there were twice as many males as females in the cohorts, and more than 65 per cent had never smoked. Contradictory to previous reports, the Black population was associated with better survival compared to white patients. Additionally, the most common comorbidities across the groups of patients that experienced a cytokine storm include:

• Hypertension (44-59 per cent)
• Diabetes (32-46 per cent)
• Cardiovascular disease (5-14 per cent)
• Chronic kidney disease (5-12 per cent)
• Cancer (5-11 per cent)
• Asthma (3-12 per cent)

“Dr Hajizadeh’s major COVID-19 research study gives timely and crucial new knowledge about using currently available anti-inflammatory drugs. This information will help others save lives,” said Kevin J Tracey, President and CEO of the Feinstein Institutes.

The researchers hope that the findings are useful for frontline providers to care for severely ill COVID-19 patients and to aid in the future design of large randomised controlled clinical trials, the gold standard of medical research.